Adherence
Adherence to dipeptidyl peptidase-4 (DPP4) inhibitor therapy has no significant association with weight change in patients with type 2 diabetes.
If you are prescribed a DPP4 inhibitor for type 2 diabetes, note that adherence does not significantly affect your weight. These medications are weight-neutral, so focus on other aspects of your treatment plan for weight management.
Adherent and poorly adherent DPP4 patients experienced approximately the same amount of weight loss.
Why this rating
Large real-world observational study (n=2,272 DPP4) with regression adjustment.
Source
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
Ginger Smith Carls et al. · Obesity Science & Practice · 2017
DOI 10.1002/osp4.116
More from this paper
- Adherence to GLP-1 receptor agonist (GLP-1RA) therapy significantly enhances weight loss in patients with type 2 diabetes, whereas poor adherence attenuates this benefit.Good
- Adherence to sulfonylurea (SU) therapy is associated with greater weight gain in patients with type 2 diabetes compared to poor adherence.Good
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →